The government is asking questions about this pharma company's painkiller and now the stock is getting crushed

Pacira Pharmaceuticals disclosed a subpoena from the Department of Justice and now the stock is getting crushed.

In a statement Thursday, the company said it has received a subpoena from the DoJ to produce documents related to how it marketed Exparel, a painkiller used after surgery.

In early afternoon trading, the stock was down by as much as 12% to near $US81 a share, the lowest its been since last June.

The company made $US188.5 million in net sales for the drug last year, which accounted for 95% of its revenues.

The Food and Drugs Administration had warned Pacira about how it advertised the drug last September. While it won approval for only 24-hour pain relief, the company said the drug worked for up to three days, according to FiercePharma.

The company said it intends to cooperate with the investigation. Pacira has a market cap of $US2.95 billion.

Here’s a chart showing the plunge in trading Thursday:

NOW WATCH: Here’s how much sex happy couples have every month

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at